Suppr超能文献

骨科器械的监管:对研究与创新的未来影响。

Regulation of orthopaedic devices: Future implications for research and innovation.

作者信息

Donnelley Claire A, Devlin Vincent J, Harris Mitchel B, Poggie Robert A, Sanders Roy W, Morshed Saam

机构信息

Institute for Global Orthopaedics and Traumatology, Department of Orthopaedic Surgery, University of California, San Francisco, San Francisco, CA.

Office of Health Technology 6, Office of Orthopedic Device, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, MD.

出版信息

OTA Int. 2021 Apr 15;4(2 Suppl). doi: 10.1097/OI9.0000000000000101. eCollection 2021 Apr.

Abstract

The conception-to-market development of orthopaedic devices occurs across the total product life cycle including device design and preclinical testing, clinical investigations to support marketing applications, and monitoring of device performance after market introduction. This process involves industry, regulatory agencies, health care providers, engineers, scientists, and patients. The Food and Drug Administration (FDA) is responsible for regulating medical devices in the United States, and uses a 3-tier classification system based on the level of control necessary to provide reasonable assurance of safety and effectiveness. Classification directs the required regulatory pathway and premarket submission type. Variations in global regulations, particularly between the United States, European Economic Area (EEA), and the United Kingdom (UK), may impact industry response to orthopaedic device development. Changing device innovation and reimbursement models have led to the consolidation of market share among larger companies. Although larger companies are better able to cope with more rigorous regulatory requirements, this leads to decreased competition and increased upward price pressure. To assist with the complex regulatory processes, the FDA offers pre-submission assistance as an opportunity for early collaboration and discussion about the medical device or device-led combination product submissions. Orthopaedic organizations, such as the Orthopaedic Trauma Association (OTA), may assist in postmarket device surveillance through the coordinated development and maintenance of clinical data registries. Such registries can longitudinally follow patients with a specific orthopaedic pathology or device usage, and monitor outcomes towards improvements in next-generation device development. As technology evolves, the nexus of regulation, industry, and patient outcome monitoring will continue to support safe and effective device innovation.

摘要

骨科器械从概念到上市的开发贯穿整个产品生命周期,包括器械设计和临床前测试、支持上市申请的临床研究以及上市后器械性能监测。这一过程涉及行业、监管机构、医疗保健提供者、工程师、科学家和患者。美国食品药品监督管理局(FDA)负责美国医疗器械的监管,并采用基于提供合理安全和有效性保证所需控制水平的三级分类系统。分类决定了所需的监管途径和上市前提交类型。全球法规的差异,特别是美国、欧洲经济区(EEA)和英国(UK)之间的差异,可能会影响行业对骨科器械开发的反应。器械创新和报销模式的变化导致了大公司市场份额的巩固。虽然大公司更有能力应对更严格的监管要求,但这导致竞争减少和价格上涨压力增大。为协助处理复杂的监管程序,FDA提供提交前协助,作为就医疗器械或器械主导的组合产品提交进行早期合作和讨论的机会。骨科组织,如骨科创伤协会(OTA),可通过协调临床数据登记处的开发和维护来协助上市后器械监测。此类登记处可纵向跟踪患有特定骨科疾病或使用特定器械的患者,并监测结果以促进下一代器械开发的改进。随着技术的发展,监管、行业和患者结果监测之间的联系将继续支持安全有效的器械创新。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85b6/10441672/a0ad58f4fc70/oi9-4-e101-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验